- Home
- FLC vs ADCT Comparison
FLC vs ADCT Comparison
Compare FLC & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLC
- ADCT
- Stock Information
- Founded
- FLC 2003
- ADCT 2011
- Country
- FLC United States
- ADCT Switzerland
- Employees
- FLC N/A
- ADCT N/A
- Industry
- FLC Trusts Except Educational Religious and Charitable
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- FLC Finance
- ADCT Health Care
- Exchange
- FLC Nasdaq
- ADCT Nasdaq
- Market Cap
- FLC 176.2M
- ADCT 143.1M
- IPO Year
- FLC N/A
- ADCT 2020
- Fundamental
- Price
- FLC $17.03
- ADCT $1.63
- Analyst Decision
- FLC
- ADCT Strong Buy
- Analyst Count
- FLC 0
- ADCT 5
- Target Price
- FLC N/A
- ADCT $8.00
- AVG Volume (30 Days)
- FLC 37.8K
- ADCT 480.5K
- Earning Date
- FLC 01-01-0001
- ADCT 03-12-2025
- Dividend Yield
- FLC 6.64%
- ADCT N/A
- EPS Growth
- FLC N/A
- ADCT N/A
- EPS
- FLC N/A
- ADCT N/A
- Revenue
- FLC N/A
- ADCT $70,717,000.00
- Revenue This Year
- FLC N/A
- ADCT $6.81
- Revenue Next Year
- FLC N/A
- ADCT $11.23
- P/E Ratio
- FLC N/A
- ADCT N/A
- Revenue Growth
- FLC N/A
- ADCT N/A
- 52 Week Low
- FLC $12.62
- ADCT $1.39
- 52 Week High
- FLC $15.45
- ADCT $5.38
- Technical
- Relative Strength Index (RSI)
- FLC 51.43
- ADCT 46.49
- Support Level
- FLC $16.93
- ADCT $1.55
- Resistance Level
- FLC $17.19
- ADCT $1.73
- Average True Range (ATR)
- FLC 0.17
- ADCT 0.12
- MACD
- FLC -0.00
- ADCT 0.03
- Stochastic Oscillator
- FLC 52.27
- ADCT 63.16
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.